Applied therapeutics announces partnership with advanz pharma for commercialization of at-007 (govorestat) in europe

New york, jan. 04, 2023 (globe newswire) -- applied therapeutics, inc. (nasdaq: aplt), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced a partnership with advanz pharma, a pharmaceutical company with a strategic focus on commercialization of specialty, hospital, and rare disease medicines, for commercialization of at-007 (govorestat) in europe.
APLT Ratings Summary
APLT Quant Ranking